Amgen to pay $762 million, pleads guilty in marketing case
NEW YORK (Reuters) – Amgen Inc pleaded guilty in a New York federal court on Tuesday for improper marketing practices involving its once top-selling Aranesp anemia drug and agreed to pay $762 million in a civil settlement and criminal fines. The world’s largest biotechnology company had previously set aside funds it expected to have to pay as a result of federal and state investigations, as well as nearly a dozen civil whistleblower lawsuits. . . .
View full post on Health News Headlines – Yahoo! News
Leave a Reply